Category Archives: Dermatology

Dermatology

Histogen Announces Online Publication in the Journal of Investigative Dermatology – Yahoo Finance

Histogen Inc

Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice

Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious andInflammatory Diseases

SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO), a clinical-stage therapeutics companyfocused on developing potential first-in-class clinical and preclinical small molecule pan-caspaseand caspase selective inhibitors that protect the bodys natural process to restore immune function, today announced the online publication of an abstract describing a preclinical study showing that emricasan has therapeutic effect against bacterial skin infections.

In the study, the role of the irreversible pan-caspase inhibitor emricasan alone and in combination with a standard-of-care antibiotic, doxycycline, was examined as potential host-directed immunotherapy against bacterial infections in vivo. Mice in four groups; placebo, placebo plus doxycycline, emricasan plus doxycycline, and emricasan alone were treated orally twice daily for 7 days after intradermal injection of the established CA-MRSA strain USA300 LAC:: lux of Staphylococcus aureus in mice. The results of the study show that: 1) emricasan alone reduced both lesion size and bacterial burden versus placebo (p<0.0001); 2) emricasan alone showed efficacy superior to doxycycline alone in lesion size (p=0.02); and 3) emricasan alone and emricasan plus doxycycline showed comparable efficacy versus placebo in both lesion size and bacterial burden (p<0.0001).

The data from this study collectively support the use of emricasan as a potential host-directed immunotherapy against MRSA skin infections, stated Steven J. Mento, President and CEO of Histogen. The fact the emricasan works as good as or better than an antibiotic alone in this preclinical study points to the opportunity to provide emricasan as a viable treatment option for physicians without the risk of generating antibiotic resistance. Following the notice from the FDA related to our recently filed IND that the Study may Proceed, we look forward to the anticipated initiation of clinical development activities using emricasan for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in the second half of 2023, concluded Dr. Mento.

Story continues

As announced previously, emricasan improved symptoms in patients infected with COVID-19 potentially employing a similar mechanism of protecting the competence of the immune system. Patients in the placebo arm who completed the study showed either delay or no symptom resolution for the duration of the study.

About Emricasan

Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of humancaspases, which are enzymes that mediate inflammation and apoptosis. Emricasan has completedextensive toxicology testing including chronic toxicology and all required carcinogenicity testing. Emricasan has previously been shown to be well tolerated in multiple clinical studies involving approximately 1,000 subjects employing multiple doses ranging from 1 mg to 500 mg orally and has been dosed chronically for up to two years in immunosuppressed patients. Emricasan was tested in a Phase 1 study in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy. Five of five patients who completed treatment with emricasan had a complete resolution of the symptoms most commonly associated with mild COVID-19 by day seven compared to zero of six on placebo. Four of five patients on emricasan compared with one of six patients on placebo were virus negative by day fourteen. The mean antibody index against COVID was 6.98 in emricasan treated patients compared to 5.32 in those receiving placebo at the end of the study on day forty-five.

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors thatprotect the bodys natural process to restore immune function. Currently, we are developingemricasan for ABSSSI as well evaluating its use for other infectious diseases. Our pipeline alsoincludes novel preclinical product candidates including CTS-2090 and other proprietary caspaseinhibitors, which are selective small molecule inhibitors of caspase-1 designed for the treatmentof certain inflammatory diseases. For more information, please visit http://www.histogen.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harborprovisions of the Private Securities Litigation Reform Act of 1995 and other Federal securitieslaws. For example, we are using forward-looking statements when we discuss the potential benefits of the preclinical study in mice showing that emricasan has therapeutic effect against bacterial skin infections; the potential benefits of emricasan, if approved; our future operations and our ability to successfully initiate, enroll and complete clinical trials, obtain clinical trial data, and achieve regulatory milestones and related timing, including those related to the initiation of clinical trials for emricasan. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Histogen that could differ materially from those described in or implied by the statements in this press release, including: our ability to obtain funding for our operations, including funding necessary to complete further development and any commercialization of our product candidates; including its ability to carry out the development of emricasan and the potential for delays in the timing of regulatory approval and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; our expectations regarding the operation of our product candidates and related benefits; our beliefs regarding the success, cost and timing of our product candidate development and current and future clinical trials and studies; our beliefs regarding the potential markets for our product candidates; any impact of the COVID-19 pandemic, or responses to the pandemic, on our business, clinical trials or personnel; our beliefs regarding our industry; our ability to attract and retain key personnel; regulatory developments in the United States and foreign countries, with respect to our product candidates; the impact of any litigation proceedings on our business and market and other conditions. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including those risks discussed in our filings with the Securities and Exchange Commission. Except as otherwise required by law, Histogen disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events, or circumstances or otherwise.

CONTACT: Susan A. KnudsonExecutive Vice President, COO & CFO Histogen Inc. ir@histogen.com

Read more:

Histogen Announces Online Publication in the Journal of Investigative Dermatology - Yahoo Finance

Dermatology

Aldena Therapeutics and Empa Awarded InnoSuisse Funding to … – StreetInsider.com

BOSTON, April 26, 2023 /PRNewswire/ -- Aldena Therapeutics Inc. (Aldena), a private biotech company pioneering siRNA-based therapies for dermatological indications, and Empa, the Swiss Federal research institute for materials science and technology,have been awarded a joint 600'000 CHF grant by InnoSuisse, the Swiss Innovation Agency. This StarCURE grant seeks to co-develop microneedle particles as a new skin delivery system, which will enable novel therapeutic approaches in dermatology by revolutionizing the way drugs are delivered and absorbed through the skin.

This groundbreaking microneedle-particle technology, called STAR particles1, now under exclusive license to Aldena was originally discovered and developed by Prof. Mark Prausnitz and Dr. Andrew Tadros at the Georgia Institute of Technology in Atlanta. These star-shaped ceramic microparticles enable delivery of large, water-soluble molecules into the skin at the site of application. Aldena Therapeutics is pioneering this technology as part of its portfolio of innovative dermatological programs.

The StarCURE collaboration between Aldena and Empawill be conducted over two years andwill aim to establish a scalable manufacturing method for STAR particles and to investigate next-generation STAR particle materials that provide added capabilities.

Dr. Claire Bouix-Peter, Chief Operating Officer of Aldena Therapeutics and project coordinator, commented: "This project is a great opportunity to leverage our expertise in dermatology in collaboration with Empa's world-class materials and science experts to transform STAR particle manufacturing for commercial-scale production."

Prof. Prausnitz, co-Founder of Aldena Therapeutics, added: "This collaboration will enable the manufacturability and expanded functionality of STAR-particle technology, which is an essential and strategic next step in the development of Aldena."

Dr. Michael Stuer, Head of the Nanopowders and Ceramics Group at Empa's High Performance Ceramics lab, remarked: "This is a great example of how our expertise in ceramic materials can be applied to develop a safe and effective drug delivery technology."

Prof. Patrik Hoffmann, Head of the Laboratory for Advanced Materials Processing at Empa, added: "This is a very exciting project and I am confident that our joint research efforts will result in a scalable technology that could revolutionize the way skin drug delivery is viewed in the pharmaceutical industry, providing treatments with greater precision, efficiency, compliance and safety."

About Aldena

Aldena Therapeutics is a Boston, Lausanne and London-based biotechnology company focusing on siRNA-based dermatological treatments, enabled by STAR particles as a novel skin delivery system, for patients suffering from dermatological diseases. It was co-founded by Prof. John Harris (MD, PhD, Professor and Chair of Dermatology at UMass Chan Medical School), Prof. Mark Prausnitz (PhD, Regents' Professor at Georgia Institute of Technology) and Dr Andrew Tadros (MD, PhD), and is backed by Medicxi. Aldena Therapeutics is pursuing multiple innovative programs and is currently initiating the IND-enabling GLP nonclinical program for its lead projects.

About Empa

Empa, the Swiss Federal Laboratories for Materials Science and Technology, is an interdisciplinary Swiss research institute conducting cutting-edge materials and technology research, based in Dbendorf, St. Gallen and Thun, Switzerland. Empa aims at generating interdisciplinary solutions to major challenges faced by the industry, and at creating the necessary scientific basis to ensure that our society develops in a sustainable manner.

1Tadros, A et al., Nature Medicine 2020, v26, p341-347 https://doi.org/10.1038/s41591-020-0787-6

View original content:https://www.prnewswire.com/news-releases/aldena-therapeutics-and-empa-awarded-innosuisse-funding-to-advance-star-particles-as-a-novel-drug-delivery-technology-for-dermatology-301807291.html

SOURCE Aldena Therapeutics

View original post here:

Aldena Therapeutics and Empa Awarded InnoSuisse Funding to ... - StreetInsider.com

Dermatology

Tralokinumab Found to be Efficacious in Adolescents With Moderate … – Dermatology Times

Interleukin-13targeted treatment with tralokinumab (Adbry; LEO Pharma)was efficacious and well tolerated in adolescents with moderate to severe atopic dermatitis (AD), according to the results of a phase 3 ECZTRA 6 randomized clinical trial.1

Lead author Amy S. Paller, MD, chair of the department of dermatology and director of the Skin Biology and Diseases Resource-Based Center of the Northwestern University Feinberg School of Medicine and attending physician at the Ann and Robert H Lurie Children's Hospital of Chicago, reported the results of the trial on tralokinumab for pediatric patients with AD who were aged 12 to 17 years.

The 52-week, randomized, double-blinded, placebo-controlled, phase 3 ECZTRA 6 trial was conducted from July 17, 2018, through March 16, 2021, at 72 centers across 10 countries in North America, Europe, Asia, and Australia. Enrolled patients were 12 to 17 years old with moderate to severe AD (Investigators Global Assessment [IGA] score 3; Eczema Area and Severity Index [EASI] 16).

The patients were randomly assigned to tralokinumab (150 or 300 mg) or placebo every 2 weeks for 16 weeks. Patients with an IGA score of 0 (clear) or 1 (almost clear) and/or 75% or higher improvement in EASI (EASI 75) at week 16 without rescue medication received maintenance treatment; other patients switched to open-label tralokinumab, 300 mg, every 2 weeks. Patients receiving placebo who met the primary end point(s) at week 16 without use of rescue medication continued to receive blinded placebo every 2 weeks until week 52.

At 16 weeks, the main goals of the phase 3 trial were for the participants to report an IGA score of 0 or 1 (clear or almost clear) and/or to report an EASI 75 score. The teams secondary objectives were to report changes in Children's Dermatology Life Quality Index from baseline to week 16, a reduction of 4 or more on the Adolescent Worst Pruritus Numeric Rating Scale, and changes in SCORing AD.

Both tralokinumab doses resulted in improvements in eczema-related sleep NRS vs placebo at week 16. Additionally, Patients receiving tralokinumab, 300 mg, every 2 weeks experienced a greater decrease in Hospital Anxiety and Depression Scale from baseline vs placebo at week 16.

Tralokinumab was well tolerated, with a majority of adverse events (AE) being mild or moderate in severity. In the initial treatment period, proportions of patients with 1 or more AE were similar among those receiving tralokinumab. The most frequent AEs were upper respiratory tract infection, dermatitis atopic (disease exacerbation), injection-site reaction, asthma, and headache.

Study authors said this is believed to be the first study to show that targeting IL-13 alone improved AD signs and symptoms along with improvements in multiple high-effect disease domains in a pediatric population. These results are consistent with tralokinumab data reported in adults with AD and suggest that specific targeting of IL-13 with tralokinumab is an effective and well-tolerated long-term treatment option for uncontrolled AD in adolescents.

Last year, the European Commission extended the marketing authorization for tralokinumab to include adolescents aged 12 to 17 with moderate to severe AD, with US agencies mulling a similar move to broaden the indication.

Reference

1. Paller AS, Flohr C, Cork M, et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol. Published online April 19, 2023. doi:10.1001/jamadermatol.2023.0627

Read more from the original source:

Tralokinumab Found to be Efficacious in Adolescents With Moderate ... - Dermatology Times

Dermatology

How Often Should You Wash Your Face? – Everyday Health

Your face experiences a lot in a day: sun, wind, makeup, the never-ending glow of screens and much more.

Caring for your skin involves cleansing, certainly, but many people are missing the mark, data suggests. More than half of people say they often skip washing their face before bedtime, according to a 2017 survey on 1,000 adult men and women from the skin-care product brand CeraVe. The brand also says that 80 percent of Americans make at least one skin-washing mistake.

As youll learn, a face-washing routine is important for the health of your facial skin. Heres what you need to know about how often to do it, if you can ever skip it, and how to cleanse correctly.

Ultimately, face cleansing is critical to maintaining healthy-looking and healthy-feeling skin, says Aanand Geria, MD, a board-certified dermatologist in Verona, New Jersey.

Your face is, well, how you face the world, and as a result, it collects dirt, oil, and other debris that can if not removed lead to irritation and other skin problems. Overall, the skin would be dirtier, drier, greasier, and older-looking without daily face cleansings, he says.

In general, wash your face twice a day. I tell patients that its important to wash your face in the morning and at the end of the day, says the Philadelphia-based board-certified dermatologist Nazanin Saedi, MD. Doing so removes impurities that may have settled on skin throughout the night and then removes dirt, impurities, and any makeup or products used during the day.

As Dr. Saedi mentions, however, there are no set guidelines. Talk to your dermatologist about what might be right for you, because it can depend on your skin type and any skin conditions you may be managing.

Although she recommends washing your face twice a day even for patients who have sensitive skin or skin conditions, some dermatologists advise only once a day in certain circumstances.

Dr. Geria recommends washing your face twice a day, too. If you have dry or sensitive skin, he says you can cleanse at night to remove dirt, but then rinse your face with warm water in the morning. Likewise, if you have an active flare-up of rosacea or eczema, you may opt to do a once-a-day wash at night to limit irritation.

Again, everyones needs are different, and if you do have rosacea, eczema, or another condition, your dermatologist can help you develop a skin-care plan that includes proper washing. They can also advise on how that plan should be modified during flare-ups.

If you were just at the gym, in a hot yoga class, or outdoors for a hike and were sweating heavily, you should wash your face, advises the American Academy of Dermatology (AAD).

Think about your skin type, makeup habits, and daily activities, says Geria. That can inform the type of products you use, as well as how you wash your skin. For example, if you wear makeup, you may want to use a makeup remover, such as micellar water or a makeup-removing balm on tough-to-remove lipstick or eye makeup before washing your skin.

Next, follow these steps from Geria:

In addition, Saedi suggests washing your face for 30 seconds. (In some cases, even longer may be more appropriate.) Ultimately, you need time to properly remove dirt and oil.

Cleansers today are specially formulated to more closely mimic the pH of the skin, so as not to overly dry out your skin or compromise the skin barrier, research notes. One problem that the CeraVe survey uncovered is that half of people use bath wash or hand soap on their face. These soaps can strip your skin of moisture and cause irritation or itchiness (which you may feel as tight skin), the aforementioned research explains. Thats why its important to use a cleanser designed specifically for the face.

Choose the cleanser that fits with your skin type. For instance, if you have dry or sensitive skin, opt for a gentle or creamy cleanser. Oily skin benefits from a gel or foam cleanser, Geria advises. If your skin is dull, an alpha hydroxy acid, or AHA, wash (such as a glycolic-based cleanser), can help remove dead skin cells on the surface and give your skin a glow, adds Saedi. Avoid harsh scrubs, which can irritate skin, she advises.

If youre traveling or are in a pinch, you can alternatively use a cleansing towelette, Saedi says. (Keep these at your bedside table if you often forget to wash your face and dont want to get up to do so.) A word of caution on these towelettes: Researchpublished in the NovemberDecember 2017 issue of Dermatitis found they often contained irritating ingredients, such as fragrances and preservatives. Stop using them if you notice any skin reaction. Consider switching to a fragrance-free brand or one labeled for sensitive skin.

The consequences depend on your skin type and condition. If you have acne and dont wash your face regularly, your breakouts may become more frequent or get worse. Washing your skin twice a day is especially important for those who have acne-prone skin, as facial cleansing removes grime from the skin and pores, which [if allowed to build up], leads to clogging and breakouts, Geria says. Research published in the February 2018 Journal of Dermatological Treatment on the right skin-washing regimen for acne is shaky at best, but the available studies do point to fewer acne lesions for twice-daily washers.

One caveat: More washing isnt better when it comes to acne, says Saedi. If you wash your face more than twice a day, then you are stripping the natural oils in your skin, and, as a result, you will end up overproducing oils.

Even if you dont wear makeup that day or dont leave your house, you still shouldnt get into bed without a wash first. Dirt, oil, and other unwanted debris can still buildup on the skin throughout the day, Saedi says. If left on, these factors can clog pores, too.

That said, like anything in health, what you do most of the time matters most. If you skip a day of face washing because youre not feeling well, had an especially late night, or just forgot, its okay. You have not ruined your skin. And you probably wont notice a thing. Ultimately, missing one day of washing your face wont significantly affect the overall health of your skin, Saedi says. Just get back into your routine tomorrow.

Dermatologists often recommend washing your skin twice a day (once in the morning and once at night) to remove dirt that has accumulated on skin as well as makeup. Whats right for your skin, however, depends on your skin type and skin conditions, so talk to your dermatologist.

Here is the original post:

How Often Should You Wash Your Face? - Everyday Health

Dermatology

Patient Preferences in Topical Psoriasis Treatment – Dermatology Times

While topical therapies continue to be a mainstay of psoriasis treatment, patient adherence is dependent on several characteristics of the medications, according to a new study.1

Researchers at the center for dermatology research in the Department of Dermatology at Wake Forest School of Medicine in Winston-Salem, North Carolina, conducted the study to better understand patient perspectives when it comes to experience, expectations, and preferences.

To do so, they analyzed results from The National Psoriasis Foundations 17- question survey conducted in March 2022, which assessed symptoms, treatment modalities, frequency of tropical therapy use, and vehicle preferences.

Of the 411 patients surveyed, 83.9% self-reported moderate psoriasis. 10.2% reported their psoriasis as severe, 5.4% reported it as mild and 0.5% reported it as very severe, with the most affected areas being the scalp (67.9%), arms/elbows ( 62.8%), trunk (61.6%) and hands/feet (40.6%).

Patient Preference

Many participants (76%) reported using topical therapy at least once weekly. Nearly 80% of participants said they would allow 2 weeks for a medication to become effective before stopping it. Participants preferred water-based creams (75.7%), followed by oil-based foam (70.8%), gel (48.7%), solution (42.8%), lotion (21.2%), non-oil-based foam (17.5%), ointment (16.5%), and spray (6.3%).

The formulation attributes rated most important were application feel (55.2%), non-staining (49.9%), quick absorption (46.7%), non-sticky texture (39.7%), ease of application (28.5%), no unpleasant smell (22.4%), non-greasy (16.8%), works quickly (14.1%), absent sting or burn (10%), no adverse skin reaction (9.7%), and once daily treatment (6.8%). If participants did not like a topical treatment's formulation, 74.7%) aid they would discontinue the use of the treatment after a week. Additionally, more than 40% of patients said that they would contact another dermatologist if their topical medication caused a reaction.

Topical medications present a particularly unique burden for dermatology patients because they can be cumbersome, difficult to use, poorly tolerated, messy, and time-consuming. In a study of topical treatment adherence among psoriasis clinical trial patients, overall adherence decreased to nearly 50% by the end of an 8-week treatment period, with small upticks in medication use observed around trial visit dates.

First-line treatments for mild-to-moderate psoriasis are topical treatments, including corticosteroids, vitamin D analogs, keratinolytics, calcineurin inhibitors, salicylic acid, and tar.1

For moderate-to-severe psoriasis, the American Academy of Dermatology recommends considering systemic therapy, including biologics, oral agents, and phototherapy, with the option to use topical medication conjunctively.2 Study authors noted that the characteristics of psoriasis treatment vehicles, and the patients reported willingness to use treatment, may be an essential consideration when planning treatment regimens.

References

1. Curcio A, Kontzias C, Gorodokin B, Feldman S, Kircik L. Patient Preferences in Topical Psoriasis Treatment. J Drugs Dermatol. 2023 Apr 1;22(4):326-332. doi: 10.36849/JDD.7372

2. How Dermatologists Diagnose and Treat Psoriasis. American Academy of Dermatology Association. https://www.aad.org/public/diseases/psoriasis/treatment. Accessed April 20, 2023.

Read the original:

Patient Preferences in Topical Psoriasis Treatment - Dermatology Times

Dermatology

Global Surgical Cameras Market to Reach $7 Billion by 2030 – Yahoo Finance

ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, April 26, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Surgical Cameras Industry" - https://www.reportlinker.com/p06033044/?utm_source=GNW Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and Chinas already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Surgical Cameras Market to Reach $7 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Surgical Cameras estimated at US$2.8 Billion in the year 2022, is projected to reach a revised size of US$7 Billion by 2030, growing at aCAGR of 12.3% over the period 2022-2030. HD & Full HD, one of the segments analyzed in the report, is projected to record 13.4% CAGR and reach US$4.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the SD segment is readjusted to a revised 10.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $754.6 Million, While China is Forecast to Grow at 18.4% CAGR

The Surgical Cameras market in the U.S. is estimated at US$754.6 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 18.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 10.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8% CAGR.

Select Competitors (Total 42 Featured)- Allied Vision Technologies GmbH- Canon Inc- Carl Zeiss AG- Leica Microsystems- Olympus Corporation- Richard Wolf GmbH- Sensor Technologies America, Inc- Smith & Nephew PLC- Sony Corporation- Videology Imaging Solutions, Inc;

Read the full report: https://www.reportlinker.com/p06033044/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEWInfluencer Market InsightsWorld Market TrajectoriesImpact of Covid-19 and a Looming Global RecessionSurgical Cameras - Global Key Competitors Percentage MarketShare in 2022 (E)Competitive Market Presence - Strong/Active/Niche/Trivial forPlayers Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVETable 1: World Recent Past, Current & Future Analysis forSurgical Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Surgical Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 3: World 16-Year Perspective for Surgical Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for SD byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2022 through 2030 and % CAGR

Table 5: World Historic Review for SD by Geographic Region -USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for SD by Geographic Region -Percentage Breakdown of Value Sales for USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for HD &Full HD by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for HD & Full HD by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR

Table 9: World 16-Year Perspective for HD & Full HD byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis forUltra HD by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Ultra HD by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR

Table 12: World 16-Year Perspective for Ultra HD by GeographicRegion - Percentage Breakdown of Value Sales for USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis forClinics & Dental Chambers by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Million for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Clinics & Dental Chambersby Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for Clinics & DentalChambers by Geographic Region - Percentage Breakdown of ValueSales for USA, Canada, Japan, China, Europe, Asia-Pacific,Latin America, Middle East and Africa for Years 2014, 2023 &2030

Table 16: World Recent Past, Current & Future Analysis forOther End-Uses by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Other End-Uses byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 18: World 16-Year Perspective for Other End-Uses byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis forHospitals by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Hospitals by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR

Table 21: World 16-Year Perspective for Hospitals by GeographicRegion - Percentage Breakdown of Value Sales for USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis forEndoscopy Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Endoscopy Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 24: World 16-Year Perspective for Endoscopy Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis forMicrosurgery Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Microsurgery Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 27: World 16-Year Perspective for Microsurgery Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis forDermatology Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 29: World Historic Review for Dermatology Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 30: World 16-Year Perspective for Dermatology Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 31: World Recent Past, Current & Future Analysis forOphthalmology Cameras by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Million for Years 2022 through 2030 and % CAGR

Table 32: World Historic Review for Ophthalmology Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 33: World 16-Year Perspective for Ophthalmology Camerasby Geographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 34: World Recent Past, Current & Future Analysis forDental Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 35: World Historic Review for Dental Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 36: World 16-Year Perspective for Dental Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 37: World Surgical Cameras Market Analysis of AnnualSales in US$ Million for Years 2014 through 2030

Table 38: World Recent Past, Current & Future Analysis forAmbulatory Surgery Centers by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Million for Years 2022 through 2030 and % CAGR

Table 39: World Historic Review for Ambulatory Surgery Centersby Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 40: World 16-Year Perspective for Ambulatory SurgeryCenters by Geographic Region - Percentage Breakdown of ValueSales for USA, Canada, Japan, China, Europe, Asia-Pacific,Latin America, Middle East and Africa for Years 2014, 2023 &2030

III. MARKET ANALYSIS

UNITED STATESSurgical Cameras Market Presence - Strong/Active/Niche/Trivial -Key Competitors in the United States for 2023 (E)Table 41: USA Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 42: USA Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 43: USA 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 44: USA Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 45: USA Historic Review for Surgical Cameras by End-Use -Clinics & Dental Chambers, Ambulatory Surgery Centers, OtherEnd-Uses and Hospitals Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 46: USA 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Table 47: USA Recent Past, Current & Future Analysis forSurgical Cameras by Type - Endoscopy Cameras, MicrosurgeryCameras, Dermatology Cameras, Ophthalmology Cameras and DentalCameras - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 48: USA Historic Review for Surgical Cameras by Type -Endoscopy Cameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 49: USA 16-Year Perspective for Surgical Cameras by Type -Percentage Breakdown of Value Sales for Endoscopy Cameras,Microsurgery Cameras, Dermatology Cameras, OphthalmologyCameras and Dental Cameras for the Years 2014, 2023 & 2030

CANADATable 50: Canada Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 51: Canada Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 52: Canada 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 53: Canada Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 54: Canada Historic Review for Surgical Cameras byEnd-Use - Clinics & Dental Chambers, Ambulatory SurgeryCenters, Other End-Uses and Hospitals Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 55: Canada 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Table 56: Canada Recent Past, Current & Future Analysis forSurgical Cameras by Type - Endoscopy Cameras, MicrosurgeryCameras, Dermatology Cameras, Ophthalmology Cameras and DentalCameras - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 57: Canada Historic Review for Surgical Cameras by Type -Endoscopy Cameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 58: Canada 16-Year Perspective for Surgical Cameras byType - Percentage Breakdown of Value Sales for EndoscopyCameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras for the Years 2014,2023 & 2030

JAPANSurgical Cameras Market Presence - Strong/Active/Niche/Trivial -Key Competitors in Japan for 2023 (E)Table 59: Japan Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 60: Japan Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 61: Japan 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 62: Japan Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 63: Japan Historic Review for Surgical Cameras by End-Use -Clinics & Dental Chambers, Ambulatory Surgery Centers, OtherEnd-Uses and Hospitals Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 64: Japan 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Table 65: Japan Recent Past, Current & Future Analysis forSurgical Cameras by Type - Endoscopy Cameras, MicrosurgeryCameras, Dermatology Cameras, Ophthalmology Cameras and DentalCameras - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 66: Japan Historic Review for Surgical Cameras by Type -Endoscopy Cameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 67: Japan 16-Year Perspective for Surgical Cameras byType - Percentage Breakdown of Value Sales for EndoscopyCameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras for the Years 2014,2023 & 2030

CHINASurgical Cameras Market Presence - Strong/Active/Niche/Trivial -Key Competitors in China for 2023 (E)Table 68: China Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 69: China Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 70: China 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 71: China Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 72: China Historic Review for Surgical Cameras by End-Use -Clinics & Dental Chambers, Ambulatory Surgery Centers, OtherEnd-Uses and Hospitals Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 73: China 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Table 74: China Recent Past, Current & Future Analysis forSurgical Cameras by Type - Endoscopy Cameras, MicrosurgeryCameras, Dermatology Cameras, Ophthalmology Cameras and DentalCameras - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 75: China Historic Review for Surgical Cameras by Type -Endoscopy Cameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 76: China 16-Year Perspective for Surgical Cameras byType - Percentage Breakdown of Value Sales for EndoscopyCameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras for the Years 2014,2023 & 2030

EUROPESurgical Cameras Market Presence - Strong/Active/Niche/Trivial -Key Competitors in Europe for 2023 (E)Table 77: Europe Recent Past, Current & Future Analysis forSurgical Cameras by Geographic Region - France, Germany, Italy,UK, Spain, Russia and Rest of Europe Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2022 through2030 and % CAGR

Table 78: Europe Historic Review for Surgical Cameras byGeographic Region - France, Germany, Italy, UK, Spain, Russiaand Rest of Europe Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 79: Europe 16-Year Perspective for Surgical Cameras byGeographic Region - Percentage Breakdown of Value Sales forFrance, Germany, Italy, UK, Spain, Russia and Rest of EuropeMarkets for Years 2014, 2023 & 2030

Table 80: Europe Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 81: Europe Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 82: Europe 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 83: Europe Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 84: Europe Historic Review for Surgical Cameras byEnd-Use - Clinics & Dental Chambers, Ambulatory SurgeryCenters, Other End-Uses and Hospitals Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 85: Europe 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Read the original here:

Global Surgical Cameras Market to Reach $7 Billion by 2030 - Yahoo Finance

Dermatology

Aesthetic Dermatology Market Expected to Growth 10.2% by 2029: Key Insights, Growth Strategies, Top Companies – openPR

Global Aesthetic Dermatology Market

The primary objective of the report is to educate business owners and assist them in making an astute investment in the market. The study highlights regional and sub-regional insights with corresponding factual and statistical analysis. The report includes first-hand, the latest data, which is obtained from the company website, annual reports, industry-recommended journals, and paid resources. The Aesthetic Dermatology market report will facilitate business owners comprehending the current trend of the market and making profitable decisions.

Grab Sample Report with Complete Graphs, Charts and Figures @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-aesthetic-dermatology-market

Aesthetic dermatology works to heal skin and hair concerns in a way that they appear healthier, even going as far as boosting self-confidence of patients who have been unhappy with the way they look. Aesthetic dermatology has grown to become an important issue in the field of dermatology. Aesthetic dermatology puts medicine in a field of tension between medical necessities and patients' wishes. Aesthetic issues are mostly relevant to dermatology because skin is not only a functional organ like heart, liver and kidneys, but a medium also of visual and tactile communication. The desire for beauty and youth is thus often expressed by patients seeking advice on the improvement of their appearance and looks.

Who Are the Global Aesthetic Dermatology Market Leading Players?

AbbVie Inc. (U.S.)Henry Schein(U.S.)Merz Pharma (Germany)Cutera (U.S.)Inc. (A Subsidiary of HologicInc.) (U.S.)Candela Medical (U.S.)Bausch Health Companies Inc. (Canada)(U.S.)Medytox (South Korea)LUTRONIC (South Korea)(South Korea)En. S.p.A. (Italy)Hoahai Biological Technology (China)REVANCE THERAPEUTICS (U.S.)Lumenis Be Ltd. (Israel)Venus Concept (Canada)Alma Lasers (Israel)Fotona (Slovenia)Aesthetic Biomedical (U.S.)(U.S.)R2 TECHNOLOGIES(A Subsidiary of INNOVATE Corp.) (U.S.)Sensus Healthcare(U.S.)Aesthetic Technology Limited (U.K.)DELEO (France)Biotech Italia Srl (France)Medency (Italy)Aerolase Corp. (U.S.)Sciton (U.S.)Image Derm(U.S.) and PhotoMedex (U.S.)

Access 350 Page Full PDF Research Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-aesthetic-dermatology-market

Aesthetic Dermatology Segmentation Analysis:

Product Type

MedicinesDevices

Surgery Type

Minimally InvasiveNon-Invasive

Treatment Type

Face TreatmentBody Treatment

Application

Skin RejuvenationSkin ResurfacingSkin TighteningHair RemovalPigmented & Vascular LesionsTattoo RemovalScarAcneDyschromiaSkin TagsPsoriasisWartsHyperhidrosisMoles And FrecklesOthers

Gender

FemaleMale

End User

HospitalsDermatology ClinicsSurgical CentresSpa ClinicsOthers

Distribution Channel

Direct TenderRetail Sales

Browse Detailed Summary of Research Report @ https://www.databridgemarketresearch.com/reports/global-aesthetic-dermatology-market

By Regions

-> North America

-> Europe

-> Japan

-> Porcelain

-> Southeast Asia

-> India

-> Korea

-> MEA

The current market dossier provides market growth potential, opportunities, industry drivers, and challenges, and market share risks along with the growth rate of the global Aesthetic Dermatology market. The report also covers currency and exchange rate fluctuations, import and export trade, and the global market.

The global Aesthetic Dermatology market and Aesthetic Dermatology market size are segmented by player and region (country), type, and application. Players, stakeholders, and other participants in the global Aesthetic Dermatology market will be able to gain the upper hand by using the report as a powerful resource. Segment analysis focuses on revenue and forecasts by type and application for the period 2022-2029. Furthermore, the Aesthetic Dermatology industry report helps up-and-coming companies make a positive assessment of their business plans as it covers a variety of topics that market players need to consider in order to remain competitive.

Aesthetic Dermatology Market Segmentation and Competitive Analysis: Apart from an overview of successful marketing strategies, market contributions and current developments of leading companies, the report also offers a dashboard with overview information on past and current performance of leading companies. The research report uses different methodologies and analysis to provide in-depth and accurate information about the Aesthetic Dermatology market.

This Aesthetic Dermatology Market Research/Analysis Report Will Provide Answers to Your Upcoming Questions

Q1. What manufacturing technology is used for Aesthetic Dermatology? What's new in this technology? What trends are causing these developments? Who are the major global players in this Aesthetic Dermatology market?

Q2. What is your company profile, product information and contact information? What Was Global Market Status of the Aesthetic Dermatology Market? What Was Capacity, Production Value, Cost and PROFIT of Aesthetic Dermatology Market? What is the current market status of the Aesthetic Dermatology industry? How is the competition in the market for this industry, both by company and by country?

Q3. What is Market Analysis of the Aesthetic Dermatology Market Considering Applications and Types?

Q4. What are the forecasts for the global Aesthetic Dermatology industry, taking into account capacity, production and production value? What will be the cost-benefit estimate? What will be the market share, supply and consumption? What about imports and exports? What Is Aesthetic Dermatology Market Chain Analysis by Upstream Raw Materials and Downstream Industries?

Q5. What Is the Economic Impact On The Aesthetic Dermatology Industry? What are the results of the analysis of the global macroeconomic environment? What are the development trends of the global macroeconomic environment? What are the market dynamics of the Aesthetic Dermatology Market? What are the challenges and opportunities?

Q6. What Should Be Entry Strategies, Countermeasures to Economic Impact, And Marketing Channels for Aesthetic Dermatology Industry?

Table of Contents:

Part 01: Executive SummaryPart 02: scope of the reportPart 03: research methodologyPart 04: IntroductionPart 05: Aesthetic Dermatology Market OverviewPart 06: Aesthetic Dermatology Market SizePart 07: Five Forces AnalysisPart 08: Aesthetic Dermatology Market Segmentation by TechnologyPart 09: Aesthetic Dermatology Market Segmentation by ApplicationPart 10: Customer LandscapePart 11: Aesthetic Dermatology Market Segmentation by End UserPart 12: regional landscapePart 13: decision frameworkPart 14: Drivers and ChallengesPart 15: Aesthetic Dermatology Market TrendsPart 16: Competitive LandscapePart 17: company profilesPart 18: Appendix

To Check the Complete Table of Contents, Click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-aesthetic-dermatology-market

Databridgemarketresearch.com always strives to provide high-quality products, believing that quality is the soul of business. Through years of efforts and the support of a large number of customer services, Databridgemarketresearch.com advisory group has accumulated creative design methods in many high-quality market research and a research team with rich experience.

View Most Popular Reports by Databridgemarketresearch.com Here:

Browse Related Reports:

https://social.kubo.chat/read-blog/9630

https://baitk.com/read-blog/11854

https://bib.az/read-blog/31472

https://wignar.com/read-blog/15521

https://yruz.one/blogs/26041/Asia-Pacific-Stem-Cell-Therapy-Market-Size-2023-Share-Growth

https://moniispace.com/read-blog/28198

https://omiyou.com/read-blog/29980

https://famenest.com/read-blog/32499

https://ubiz.chat/read-blog/35586

https://geto.space/read-blog/107243

https://uchatoo.com/read-blog/11860

https://social.kubo.chat/read-blog/9633

https://baitk.com/read-blog/11856

https://bib.az/read-blog/31476

https://wignar.com/read-blog/15522

https://yruz.one/blogs/26051/Middle-East-Africa-Stem-Cell-Therapy-Market-Size-Business-Statistics

https://moniispace.com/read-blog/28199

https://omiyou.com/read-blog/29982

https://famenest.com/read-blog/32501

https://ubiz.chat/read-blog/35589

https://geto.space/read-blog/107247

https://uchatoo.com/read-blog/11863

https://social.kubo.chat/read-blog/9636

https://baitk.com/read-blog/11859

https://bib.az/read-blog/31479

https://wignar.com/read-blog/15524

https://yruz.one/blogs/26059/North-America-Stem-Cell-Therapy-Market-Size-Share-Growth-Trend

https://moniispace.com/read-blog/28204

https://omiyou.com/read-blog/29986

https://famenest.com/read-blog/32505

https://ubiz.chat/read-blog/35591

https://geto.space/read-blog/107252

https://uchatoo.com/read-blog/11866

https://social.kubo.chat/create-blog/

https://baitk.com/read-blog/11865

https://bib.az/read-blog/31484

https://wignar.com/read-blog/15528

https://yruz.one/blogs/26067/Age-Related-Macular-Degeneration-AMD-Market-Product-Types-Competitive-Landscape

https://moniispace.com/read-blog/28210

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475E-Mail: Corporatsesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than

5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.

Originally posted here:

Aesthetic Dermatology Market Expected to Growth 10.2% by 2029: Key Insights, Growth Strategies, Top Companies - openPR

Dermatology

How, where to get medical records from closed Myrtle Beach dermatology office – wpde.com

MYRTLE BEACH, S.C. (WPDE)

Thousands of local dermatology patients are one step closer to getting their medical records back after Dermatology and Skin Cancer Center SC closed without warning in February.

It has now been more than 40 days that patients haven't been able to access their records, and many of these patients have cancer.

ABC15 first broke the story afterseveral patients reached out to us to investigate the unexpected closure.

READ MORE: Patients say MB dermatology office closes, fails to disclose medical records, requests

The office abruptly closed without warning to either employees, and patients, on February 17, and never reopened.

Initially, ABC15reached out to the South Carolina Department of Labor Licensing and Regulationin March to askhow patients could get their records back.

Now, alongside the state Board of Medical Examiners, they have officially enacted a petition appointing another doctor as the custodian for these records.

Dermatology and Skin Cancer Center SC Myrtle Beach office (Credit: Emma Parkhouse/WPDE)

Here's how to do it.

The Board confirmed the associated medical offices were closed down after a transfer of ownership fell through.

The initial owner, Dr. Joseph Masessa, died in 2019.

His practice was taken over by his brother, Jeffery Masessa, who is not a licensed physician in South Carolina.

According to the Board, Jeffery never reached out to the state's labor department or the Board about the closure; or made any arrangements for record retrieval.

SUGGESTED: Patients can retrieve records after Myrtle Beach dermatology office unexpectedly closed

The board determined while Jeffery Masessa may have once been considered a "responsible party at one point in time", he no longer is.

In addition, because Dr. Joseph Masessa is deceased, the Board has the legal authority to appoint a custodian of the records.

Board-certified surgeon and dermatologist, Dr. Brandon Coakley at Waccamaw Dermatology has been selected as that custodian.

"Patients have been panicked. There's patients that went into the doctor's office and were told, 'hey, you have a spot that's suspicious for cancer'; a biopsy was taken, and then there was no answer," said Coakley.

Waccamaw Dermatology office in Myrtle Beach (Credit: Emma Parkhouse/WPDE)

Dr. Coakley told ABC15 according to the closed office's former manager,Dermatology and Skin Cancer Center SC in Myrtle Beach had roughly 36,000 patient visits in 2022.

Even if those patients attended the office multiple times throughout the year, Coakley says there will be at least 10,000 patients impacted by this.

He's still waiting to hear back about a confirmed number of patient files.

While he's not sure exactly how many thousands of records there are at the moment, Dr. Coakley is sure that he wants to help these patients in anyway he can.

"We will be contacting, as per the medical board's order, contacting every patient to let them know that we have the records," said Coakley. "I don't know the state of the paper records. My plan is to contact everybody who had an email on file electronically because that's faster and easier, but we will go through the process of organizing the paper records and notifying those people by regular first class mail."

Dr. Coakley and his office staff at Waccamaw Dermatology will be receiving all of the paper and digital records from Dermatology and Skin Cancer Center SC over the next couple of days.

Waccamaw Dermatology andDermatology and Skin Cancer Center SC are not associated or affiliated with each other.

NEW: Trump surrenders at Manhattan courthouse ahead of arraignment in hush money case

ABC15 got ahold of Jeffery Masessa Tuesday afternoon.

Over the phone, our reporter asked him if he was available for an interview to talk about the closing of the dermatology offices he owns in South Carolina.

He agreed to an interview and said he would call back after a meeting to set it up. Since then, he has not returned any phone calls or texts.

The Board and the state LLR have stated they have still not heard from, or been able to get in contact, with Jeffery Masessa.

Dr. Coakley says he and his team will be working as quickly as possible to obtain and organize the records as they prepare to directly contact everyone whose been affected.

Updates on obtaining medical records for former patients ofDermatology and Skin Cancer Center SC will be posted here.

His office is located at 5046 Highway 17 Bypass South, in Suite 200.

This is a developing story. Stay with ABC15 News for updates.

Original post:

How, where to get medical records from closed Myrtle Beach dermatology office - wpde.com

Dermatology

Dermatology Month in Review: Highlights from March 2023 – MD Magazine

This past month on HCPLive, several important topics were covered as part of our dermatology content from March.

The list includes new trial data on psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and prurigo nodularis (PN) treatment options.

The following list is a summary of these major breakthroughs covered in March in the dermatology space, with more news and updated content on these topics available on the HCPLive main news page.

1. Positive Phase 3 Trial Results for Tapinarof Cream on Atopic Dermatitis

In this HCPLive article, phase 3 data from the ADORING 2 trial indicated that about of half of AD patients treated with tapinarof, 1% showed improvement on the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM).

The investigators noted that tapinarof may be potential two-in-one first-line topical treatment for both atopic dermatitis and plaque psoriasis, as the new trial found the cream to be both safe and tolerable for all age groups down to 2 years.

The study results were announced by biopharmaceutical company Dermavant Sciences.

2. Positive Trial Results for Hand, Foot Eczema Patients Treated with Dupilumab

This late-breaking data was shown at the American Academy of Dermatology (AAD) 2023 conference, showing that about 40% of uncontrolled moderate-to-severe hand and foot AD patients achieved clear or almost clear skin compared to 17% with placebo.

The researchers saw improvements as early as 1 week, noting that there were substantial improvements in measures of sleep, skin pain, as well as hand eczema-related life quality. They noted that the drug was the first biologic evaluated for this particular patient population.

The data was presented by Eric Simpson, MD, the studys principal trial investigator.

3. Nemolizumab Treatment Led to Improved Skin Lesions, Itch for Prurigo Nodularis Patients

Phase 3 data from the OLYMPIA 2 trial, presented at AAD, showed that nemolizumab monotherapy improved skin lesions, itch, and sleep disturbances in adults with moderate-to-severe prurigo nodularis (PN).

The investigators reported that nemolizumab, a first-in-class, interleukin-31 receptor alpha antagonist, met all of the studys primary and key secondary endpoints.

The late-breaking results were presented by Shawn Kwatra, MD, from Johns Hopkins University School of Medicine.

4. Once Daily Roflumilast Improved Symptoms of Atopic Dermatitis in Phase 3 Trials

This late-breaking data, presented at AAD, showed that roflumilast 0.15% once-daily improved AD across multiple efficacy endpoints and produced favorable safety and tolerability in patients.

The results showed that adverse events (AEs) were reported in less than 3.5% of patients, and application site pain incidence was low. The data resulted from the INTEGUMENT-1 and INTEGUMENT-2 studies.

The results were presented by Lawrence Eichenfield, MD, from Rady Children's Hospital.

5. Phase 3 Trial Data on Bimekizumab for Patients with Hidradenitis Suppurativa

This data, also presented at AAD, indicated that a greater percentage of HS patients achieved HiSCR50 for those treated with bimekizumab compared to placebo at week 16 of the study.

The results came from the BE HEARD I and II trials investigating the selective inhibition of IL-17F and IL-17A by bimekizumb, a monoclonal IgG1 antibody.

The research was presented at the conference by lead investigator Alexa B. Kimball, MD, from Beth Israel Deaconess Medical Center.

6. Oral Roflumilast Effective, Safe in Treating Plaque Psoriasis Over 24 Weeks

In this study, oral roflumilast treatment was found to lead to significant Psoriasis Area and Severity Index (PASI) score, with 34.8% of their treatment group reached PASI75 compared to 0.0% in given placebo by week 12.

The late-breaking data on oral roflumilast, a targeted phosphodiesterase (PDE)-4 inhibitor, was presented at AAD 2023. The research team also stated that roflumilast may become a cheap alternative treatment to other psoriasis drugs with more research.

The findings were presented by Alexander Egeberg, MD, PhD, from the University of Copenhagen and Bispebjerg Hospital.

7. Oral TYK2 Inhibitor Led to Significant Skin Clearance Improvement in Psoriasis

These results showed that treatment with TAK-279 (formerly NDI-034858), an oral tyrosine kinase 2 (TYK2) inhibitor, led to significant skin clearance improvement for moderate-to-severe psoriasis patients compared to placebo, especially at a once-daily, 5 mg dose.

The phase 2b clinical trial data was shown at AAD, and the investigators demonstrated that at the highest dose of TAK-279, 33% of study participants reached complete skin clearance by week 12.

The data was presented at the conference by April W. Armstrong, MD, MPH, from USCs Keck School of Medicine.

Read this article:

Dermatology Month in Review: Highlights from March 2023 - MD Magazine